Alpha 2.0
Login Register
» Articles » PMID: 32205092

TH17 Responses in Cytokine Storm of COVID-19: An Emerging Target of JAK2 Inhibitor Fedratinib

Overview
Journal J Microbiol Immunol Infect
Specialties Allergy & Immunology
Microbiology
Date 2020 Mar 25
PMID 32205092
Citations 459
Authors
Dandan Wu
Xuexian O Yang
Affiliations
Soon will be listed here.
Abstract

COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles.

Citing Articles

COVID-19: A threat to the respiratory system.

Rasool G, Khan W, Khan A, Riaz M, Abbas M, Rehman A Int J Immunopathol Pharmacol. 2024; 38:3946320241310307.

PMID: 39716038 PMC: 11672396. DOI: 10.1177/03946320241310307.

Cyclosporine and fedratinib combination therapy via modulating Th17/Treg balance in Rat model of membranous glomerulonephritis.

Ghassabi A, Hosseini M, Abdoli Goungormaz H, Soltani-Zangbar M, Beomidehagh M, Rostamzadeh D Biochem Biophys Rep. 2024; 40:101874.

PMID: 39655266 PMC: 11626047. DOI: 10.1016/j.bbrep.2024.101874.

Age Differences and Prevalence of Comorbidities for Death and Survival in Patients with COVID-19: A Single-Center Observational Study in a Region of Southern Italy.

Santella B, Aliberti S, Fortino L, Donato A, Andretta V, Santoro E Life (Basel). 2024; 14(11).

PMID: 39598175 PMC: 11595941. DOI: 10.3390/life14111376.

Immunity and Coagulation in COVID-19.

Avdonin P, Blinova M, Serkova A, Komleva L, Avdonin P Int J Mol Sci. 2024; 25(20).

PMID: 39457048 PMC: 11508857. DOI: 10.3390/ijms252011267.

MicroRNAs are enriched at COVID-19 genomic risk regions, and their blood levels correlate with the COVID-19 prognosis of cancer patients infected by SARS-CoV-2.

Anfossi S, Darbaniyan F, Quinlan J, Calin S, Shimizu M, Chen M Mol Cancer. 2024; 23(1):235.

PMID: 39434078 PMC: 11492698. DOI: 10.1186/s12943-024-02094-9.

References
1.
Zenewicz L . IL-22: There Is a Gap in Our Knowledge. Immunohorizons. 2019; 2(6):198-207. PMC: 10518850. DOI: 10.4049/immunohorizons.1800006. View
2.
Bermejo-Martin J, Ortiz de Lejarazu R, Pumarola T, Rello J, Almansa R, Ramirez P . Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza. Crit Care. 2009; 13(6):R201. PMC: 2811892. DOI: 10.1186/cc8208. View
3.
Tse G, To K, Chan P, Lo A, Ng K, Wu A . Pulmonary pathological features in coronavirus associated severe acute respiratory syndrome (SARS). J Clin Pathol. 2004; 57(3):260-5. PMC: 1770245. DOI: 10.1136/jcp.2003.013276. View
4.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497-506. PMC: 7159299. DOI: 10.1016/S0140-6736(20)30183-5. View
5.
Li C, Yang P, Sun Y, Li T, Wang Z, Zou Z . IL-17 response mediates acute lung injury induced by the 2009 pandemic influenza A (H1N1) virus. Cell Res. 2011; 22(3):528-38. PMC: 3292301. DOI: 10.1038/cr.2011.165. View